How many drug targets are there?
The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
For the past decade, the number of molecular targets for approved drugs has been debated. Here, we reconcile apparently contradictory previous reports into a comprehensive survey, and propose a consensus number of current drug targets for all classes of approved therapeutic drugs. One striking feature is the relatively constant historical rate of target innovation (the rate at which drugs against new targets are launched); however, the rate of developing drugs against new families is significantly lower. The recent approval of drugs that target protein kinases highlights two additional trends: an emerging realization of the importance of polypharmacology, and also the power of a gene-family-led approach in generating novel and important therapies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, G-protein-coupled receptors (GPCRs) are influenced by trafficking progress and then internalized in the cell membrane and recycled or degraded.”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [127]
In the citing paper
“Covalent molecules may not be able to effectively target GPCRs during this turnover process [127].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [127]
Citations
Cites
Berman, H. M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.235 · Cited by 40,196
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
The Pfam Protein Families Database
Bateman, A. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.1.276 · Cited by 14,000
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Murzin, A. G., Brenner, S. E., Hubbard, T., & Chothia, C. (1995) · Journal of Molecular Biology · doi:10.1016/s0022-2836(05)80134-2 · Cited by 7,012 · cited 1×
“Patterns in drug targets In order to identify the familial relationships between all drug targets, we analysed the presence of domains, using the SCO”
MethodDrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305 · cited 1×
“drugs acted primarily through only 120 underlying molecular target”
BackgroundSelf-citationThe Pfam protein families database
Bateman, A. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh121 · Cited by 3,127
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967 · cited 1×
“Imatinib, originally developed as a highly selective inhibitor of c-AB”
BackgroundA small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W. H., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,892 · cited 1×
“(and which target association led to its first approval for chronic myeloid leukaemia), has subsequently been discovered to be have significant activity against several other clinically relevant kinases, such as c-KI”
Background
Research works printed but not linked: 1
- Christensen, C. M. The Innovator's Dilemma: When New Technologies Cause Great Firms to Fail (Harvard Business School Press, Cambridge, 1997).
Cited by
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
Self-citationDrugBank: a knowledgebase for drugs, drug actions and drug targets
Wishart, D. S., Knox, C., Guo, A. C., Cheng, D., Shrivastava, S., Tzur, D., Gautam, B., & Hassanali, M. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkm958 · Cited by 2,861
“(18).”
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788
“Perhaps an important emphasis for future MAPK drug discovery should be to consider targets that are not classically considered attractive and 'druggable' targets (Overington et al., 2006), yet are clearly important modulators of MAPK function.”
BackgroundTrends in GPCR drug discovery: new agents, targets and indications
Hauser, A. S., Attwood, M. M., Rask-Andersen, M., Schiöth, H. B., & Gloriam, D. E. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.178 · Cited by 2,627
A comprehensive map of molecular drug targets
Santos, R., Ursu, O., Gaulton, A., Bento, A. P., Donadi, R. S., Bologa, C. G., Karlsson, A., Al-Lazikani, B., Hersey, A., Oprea, T. I., et al. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.230 · Cited by 2,427
“The simplest view would be that small-molecule drugs for which poly pharmacology is required for their action, such as sunitinib, are more likely to have been discovered through phenotypic rather than targeted screens.”
BackgroundMethodInfluentialSelf-citationQuantifying the chemical beauty of drugs
Bickerton, G. R., Paolini, G. V., Besnard, J., Muresan, S., & Hopkins, A. L. (2012) · Nature Chemistry · doi:10.1038/nchem.1243 · Cited by 2,242
“Methods Data set of known drugs A non-redundant data set comprising 771 approved drugs was derived from the ChEMBL DrugStore databas”
Self-citationDesigning antimicrobial peptides: form follows function
Fjell, C. D., Hiss, J. A., Hancock, R. E. W., & Schneider, G. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3591 · Cited by 2,035
“For example, the aminolaurylacylated AMP sequence ALWKTLLKKVLKA exhibits improved bacteri cidal properties and is less prone to degradation by plasma proteases than the unmodified peptide 42 .”
BackgroundDiagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
“Since the dawn of the genomics era in the 1990s, the main focus of drug discovery has been on drug targets, which are typically proteins that appear to have a key role in disease pathogenesi”
BackgroundYıldırım, M. A., Goh, K.-I., Cusick, M. E., Barabási, A.-L., & Vidal, M. (2007) · Nature Biotechnology · doi:10.1038/nbt1338 · Cited by 1,708
Non-uniform refinement: adaptive regularization improves single-particle cryo-EM reconstruction
Punjani, A., Zhang, H., & Fleet, D. J. (2020) · Nature Methods · doi:10.1038/s41592-020-00990-8 · Cited by 1,683
Emerging applications of metabolomics in drug discovery and precision medicine
Wishart, D. S. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.32 · Cited by 1,488
Induced protein degradation: an emerging drug discovery paradigm
Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486
Bennett, C. F., & Swayze, E. E. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105654 · Cited by 1,374
Electrostatic Interactions in Protein Structure, Folding, Binding, and Condensation
Zhou, H.-X., & Pang, X. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00305 · Cited by 1,190
Photopharmacology: Beyond Proof of Principle
Velema, W. A., Szymanski, W., & Feringa, B. L. (2014) · Journal of the American Chemical Society · doi:10.1021/ja413063e · Cited by 1,178
GPCRdb: an information system for G protein-coupled receptors
Isberg, V., Mordalski, S., Munk, C., Rataj, K., Harpsøe, K., Hauser, A. S., Vroling, B., Bojarski, A. J., Vriend, G., & Gloriam, D. E. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1178 · Cited by 1,072
“GPCRs constitute the targets of more than a quarter of all FDA approved drugs (6), but the majority, including 58% of the Class A receptors, are still unexploited in therapies/trials (7).”
BackgroundStructure-Function of the G Protein–Coupled Receptor Superfamily
Katritch, V., Cherezov, V., & Stevens, R. C. (2013) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-032112-135923 · Cited by 1,054
The genome of the blood fluke Schistosoma mansoni
Berriman, M., Haas, B. J., LoVerde, P. T., Wilson, R. A., Dillon, G. P., Cerqueira, G. C., Mashiyama, S. T., Al-Lazikani, B., Andrade, L. F., Ashton, P. D., et al. (2009) · Nature · doi:10.1038/nature08160 · Cited by 1,058
Self-citationLiu, X., Ouyang, S., Yu, B., Liu, Y., Huang, K., Gong, J., Zheng, S., Li, Z., Li, H., & Jiang, H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq300 · Cited by 967
Opportunities and challenges in phenotypic drug discovery: an industry perspective
Moffat, J. G., Vincent, F., Lee, J. A., Eder, J., & Prunotto, M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.111 · Cited by 939
Long-Lived Emissive Probes for Time-Resolved Photoluminescence Bioimaging and Biosensing
Zhang, K. Y., Yu, Q., Wei, H., Liu, S., Zhao, Q., & Huang, W. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00425 · Cited by 923
The productivity crisis in pharmaceutical R&D
Pammolli, F., Magazzini, L., & Riccaboni, M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3405 · Cited by 918
Muratov, E. N., Bajorath, J., Sheridan, R. P., Tetko, I. V., Filimonov, D., Poroikov, V., Oprea, T. I., Baskin, I. I., Varnek, A., Roitberg, A., et al. (2020) · Chemical Society Reviews · doi:10.1039/d0cs00098a · Cited by 913
Structure and dynamics of molecular networks: A novel paradigm of drug discovery
Csermely, P., Korcsmáros, T., Kiss, H. J. M., London, G., & Nussinov, R. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.016 · Cited by 892
“However, it is worth to note that looking only at the number of new drugs without considering their therapeutic value omits an important factor in the analysis (Austin, 2006; Overington et al., 2006; Chong & Sullivan, 2007; Bunnage, 2011; Edwards et al., 2011; Scannell et al., 2012).”
BackgroundMacromolecular modeling and design in Rosetta: recent methods and frameworks
Leman, J. K., Weitzner, B. D., Lewis, S. M., Adolf-Bryfogle, J., Alam, N., Alford, R. F., Aprahamian, M., Baker, D., Barlow, K. A., Barth, P., et al. (2020) · Nature Methods · doi:10.1038/s41592-020-0848-2 · Cited by 888
Trends in the exploitation of novel drug targets
Rask-Andersen, M., Almén, M. S., & Schiöth, H. B. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3478 · Cited by 853
Pawson, A. J., Sharman, J. L., Benson, H. E., Faccenda, E., Alexander, S. P. H., Buneman, O. P., Davenport, A. P., McGrath, J. C., Peters, J. A., Southan, C., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1143 · Cited by 849
Targeted delivery of low molecular drugs using chitosan and its derivatives
Park, J. H., Saravanakumar, G., Kim, K., & Kwon, I. C. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.10.003 · Cited by 821
“Recent comprehensive surveys also disclosed that many molecular targets have been explored for therapeutic interventions, and most of the drugs approved for these targets are from small molecules [27].”
BackgroundStructure of the human histamine H1 receptor complex with doxepin
Shimamura, T., Shiroishi, M., Weyand, S., Tsujimoto, H., Winter, G., Katritch, V., Abagyan, R., Cherezov, V., Liu, W., Han, G. W., et al. (2011) · Nature · doi:10.1038/nature10236 · Cited by 804
“Many of these compounds inhibit the action of histamine on H 1 R to alleviate the symptoms of allergic reactions, making H 1 R one of the most validated drug targets judging from the number of drugs approve”
Reducing safety-related drug attrition: the use of in vitro pharmacological profiling
Bowes, J., Brown, A. J., Hamon, J., Jarolimek, W., Sridhar, A., Waldron, G., & Whitebread, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3845 · Cited by 748
Principles for targeting RNA with drug-like small molecules
Warner, K. D., Hajdin, C. E., & Weeks, K. M. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.93 · Cited by 749
Pan, S.-Y., Zhou, S.-F., Gao, S.-H., Yu, Z.-L., Zhang, S.-F., Tang, M.-K., Sun, J.-N., Ma, D.-L., Han, Y.-F., Fong, W.-F., et al. (2013) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2013/627375 · Cited by 687
Molecular Dynamics Simulations in Drug Discovery and Pharmaceutical Development
Salo-Ahen, O. M. H., Alanko, I., Bhadane, R., Bonvin, A. M. J. J., Honorato, R. V., Hossain, S., Juffer, A. H., Kabedev, A., Lahtela-Kakkonen, M., Larsen, A. S., et al. (2020) · Processes · doi:10.3390/pr9010071 · Cited by 659
Novel trends in high-throughput screening
Mayr, L. M., & Bojanic, D. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.08.004 · Cited by 694
Tang, J., Szwajda, A., Shakyawar, S., Xu, T., Hintsanen, P., Wennerberg, K., & Aittokallio, T. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci400709d · Cited by 645
Drug–target interaction prediction: databases, web servers and computational models
Chen, X., Yan, C. C., Zhang, X., Zhang, X., Dai, F., Yin, J., & Zhang, Y. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbv066 · Cited by 658
The impact of natural products upon modern drug discovery
Ganesan, A. (2008) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2008.03.016 · Cited by 646
Targeting RNA with Small Molecules
Thomas, J. R., & Hergenrother, P. J. (2008) · Chemical Reviews · doi:10.1021/cr0681546 · Cited by 647
G protein-coupled receptors: structure- and function-based drug discovery
Yang, D., Zhou, Q., Labroska, V., Qin, S., Darbalaei, S., Wu, Y., Yuliantie, E., Xie, L., Tao, H., Cheng, J., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00435-w · Cited by 632
THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels
Alexander, S. P. H., Mathie, A., Peters, J. A., Veale, E. L., Striessnig, J., Kelly, E., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., et al. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14749 · Cited by 606
Evolutionary Conservation of Human Drug Targets in Organisms used for Environmental Risk Assessments
Gunnarsson, L., Jauhiainen, A., Kristiansson, E., Nerman, O., & Larsson, D. G. J. (2008) · Environmental Science & Technology · doi:10.1021/es8005173 · Cited by 594
Regulation of membrane protein structure and function by their lipid nano-environment
Levental, I., & Lyman, E. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-022-00524-4 · Cited by 575
“A non- exclusive alternative is that PIP2- binding signals the arrival of potassium channels on the plasma membrane (where PIP2 is enriched; Fig.”
BackgroundMethodInfluentialTherapeutic opportunities within the DNA damage response
Pearl, L. H., Schierz, A. C., Ward, S. E., Al-Lazikani, B., & Pearl, F. M. G. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3891 · Cited by 587
Self-citationTarget profiling of small molecules by chemical proteomics
Rix, U., & Superti-Furga, G. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.216 · Cited by 575
“Considering that there are hundreds of thousands of different proteins—not to mention splice isoforms, post-translational modifications (PTMs) and mutants, leading to an estimated 3,000–10,000 druggable targets—there should be significant potential to move beyond the approximately 500 currently exploited targets for t…”
BackgroundProgress of Lead‐Free Halide Double Perovskites
Igbari, F., Wang, Z., & Liao, L. (2019) · Advanced Energy Materials · doi:10.1002/aenm.201803150 · Cited by 562
The Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12445 · Cited by 556
Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
“This strategy of combining drug elements that can hit multiple targets (‘polypharmacology’ [1562-1564]) has much to commend it, including on theoretical grounds, and we discuss these in the section on systems biology below.”
BackgroundNormal Mode Analysis of Biomolecular Structures: Functional Mechanisms of Membrane Proteins
Bahar, I., Lezon, T. R., Bakan, A., & Shrivastava, I. H. (2010) · Chemical Reviews · doi:10.1021/cr900095e · Cited by 537
Drug–target interaction prediction by random walk on the heterogeneous network
Chen, X., Liu, M.-X., & Yan, G.-Y. (2012) · Molecular BioSystems · doi:10.1039/c2mb00002d · Cited by 533
Overcoming the challenges of membrane protein crystallography
Carpenter, E. P., Beis, K., Cameron, A. D., & Iwata, S. (2008) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2008.07.001 · Cited by 525
“Membrane proteins represent between 20 and 30% of the proteomes of most organisms [1] and more than 40% of drug targets [2] and yet very few structures of these molecules have been solved by X-ray crystallography or NMR.”
BackgroundTargeting long non-coding RNA to therapeutically upregulate gene expression
Wahlestedt, C. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4018 · Cited by 532
The RCSB Protein Data Bank: views of structural biology for basic and applied research and education
Rose, P. W., Prlić, A., Bi, C., Bluhm, W. F., Christie, C. H., Dutta, S., Green, R. K., Goodsell, D. S., Westbrook, J. D., Woo, J., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1214 · Cited by 515
Probing the links between in vitro potency, ADMET and physicochemical parameters
Gleeson, M. P., Hersey, A., Montanari, D., & Overington, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3367 · Cited by 503
“jpg"/> The past two decades have seen the evolution of chemical lead discovery strategies in the pharmaceutical industry, increasingly focusing on speed and efficiency of chemical synthesis and biological screening, in order to satisfy the greater desire for potent, selective small molecules for novel drug target”
Self-citationPhenotypic screening in cancer drug discovery — past, present and future
Moffat, J. G., Rudolph, J., & Bailey, D. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4366 · Cited by 507
Kibble, M., Saarinen, N., Tang, J., Wennerberg, K., Mäkelä, S., & Aittokallio, T. (2015) · Natural Product Reports · doi:10.1039/c5np00005j · Cited by 489
Three-Dimensional Structures of Membrane Proteins from Genomic Sequencing
Hopf, T. A., Colwell, L. J., Sheridan, R., Rost, B., Sander, C., & Marks, D. S. (2012) · Cell · doi:10.1016/j.cell.2012.04.012 · Cited by 512
“More than 25% of all human proteins have integral membrane domains; many of these are medically important, with nearly half of all drug targets containing a membrane domain (Bakheet and Doig, 2009; Overington et al., 2006).”
High-throughput electrophysiology: an emerging paradigm for ion-channel screening and physiology
Dunlop, J., Bowlby, M., Peri, R., Vasilyev, D., & Arias, R. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2552 · Cited by 498
Revisiting lab-on-a-chip technology for drug discovery
Neužil, P., Giselbrecht, S., Länge, K., Huang, T. J., & Manz, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3799 · Cited by 487
Generic GPCR residue numbers – aligning topology maps while minding the gaps
Isberg, V., de Graaf, C., Bortolato, A., Cherezov, V., Katritch, V., Marshall, F. H., Mordalski, S., Pin, J.-P., Stevens, R. C., Vriend, G., et al. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.11.001 · Cited by 492
“Their abundance in human physiological systems, as well as their accessibility and druggability, have made them a major drug target family – (cid:2) 30% of the marketed drugs act on GPCRs [3].”
BackgroundTherapeutic target database update 2012: a resource for facilitating target-oriented drug discovery
Zhu, F., Shi, Z., Qin, C., Tao, L., Liu, X., Xu, F., Zhang, L., Song, Y., Liu, X., Zhang, J., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr797 · Cited by 480
“drug approval, clinical trial or investigations) of the corresponding drugs as confirmed by biochemical assay and strong cell based and/or in vivo evidence linking the target to drug (15,17,22).”
BackgroundPolypharmacology – Foe or Friend?
Peters, J.-U. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400856t · Cited by 465
Targeting receptor-mediated endocytotic pathways with nanoparticles: Rationale and advances
Xu, S., Olenyuk, B. Z., Okamoto, C. T., & Hamm-Alvarez, S. F. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.041 · Cited by 467
IBM Watson: How Cognitive Computing Can Be Applied to Big Data Challenges in Life Sciences Research
Chen, Y., Elenee Argentinis, J., & Weber, G. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.12.001 · Cited by 466
Patching, S. G. (2014) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2013.04.028 · Cited by 458
Fragment-Based Approaches in Drug Discovery and Chemical Biology
Scott, D. E., Coyne, A. G., Hudson, S. A., & Abell, C. (2012) · Biochemistry · doi:10.1021/bi3005126 · Cited by 460
León, R., Garcia, A. G., & Marco‐Contelles, J. (2013) · Medicinal Research Reviews · doi:10.1002/med.20248 · Cited by 440
Furukawa, T., Kuboki, Y., Tanji, E., Yoshida, S., Hatori, T., Yamamoto, M., Shibata, N., Shimizu, K., Kamatani, N., & Shiratori, K. (2011) · Scientific Reports · doi:10.1038/srep00161 · Cited by 440
“The GPCR pathway involving PKA is already known to be a major target of drug development, and indeed one-third of current drugs target GPCR pathway”
BackgroundMalaria medicines: a glass half full?
Wells, T. N. C., van Huijsduijnen, R. H., & Van Voorhis, W. C. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4573 · Cited by 430
Small-molecule hydrophobic tagging–induced degradation of HaloTag fusion proteins
Neklesa, T. K., Tae, H. S., Schneekloth, A. R., Stulberg, M. J., Corson, T. W., Sundberg, T. B., Raina, K., Holley, S. A., & Crews, C. M. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.597 · Cited by 429
“(a) Chemical structures of the representative Halotag ligands: Hyt5 (1), Hyt12 ( 2), Hyt13 (3), Hyt16 (4), Hyt21 (5) and Hyt22 (6).”
BackgroundThe Expanding Role of Pyridine and Dihydropyridine Scaffolds in Drug Design
Ling, Y., Hao, Z.-Y., Liang, D., Zhang, C.-L., Liu, Y.-F., & Wang, Y. (2021) · Drug Design, Development and Therapy · doi:10.2147/dddt.s329547 · Cited by 414
Target deconvolution strategies in drug discovery
Terstappen, G. C., Schlüpen, C., Raggiaschi, R., & Gaviraghi, G. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2410 · Cited by 429
“This approach, which was thought to be more rational and efficient, was spurred on by the sequencing of the human genome and the arrival of a new era in which knowledge of the gene sequences of all potential drug targets is availabl”
BackgroundVan Voorhis, W. C., Adams, J. H., Adelfio, R., Ahyong, V., Akabas, M. H., Alano, P., Alday, A., Alemán Resto, Y., Alsibaee, A., Alzualde, A., et al. (2016) · PLOS Pathogens · doi:10.1371/journal.ppat.1005763 · Cited by 435
“G protein-coupled receptors (GPCRs) represent the largest human drug target class [9]; they affect neurological and cardiovascular physiology and are included in routine safety pharmacology panels [10].”
The Concise Guide to PHARMACOLOGY 2013/14: Enzymes
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12451 · Cited by 425
Yu, H., Chen, J., Xu, X., Li, Y., Zhao, H., Fang, Y., Li, X., Zhou, W., Wang, W., & Wang, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037608 · Cited by 423
“Interestingly, it is found that MDMA binds to the A-1A adrenergic receptor (ADRA1A, binding score = 0.764) and A-2A adrenergic receptor (ADRA2A, binding score = 0.802), which are the targets of 4- methoxyamphetamine (DB01472) [22], a compound structurally similar to MDMA (Figure 9).”
BackgroundMethodInfluentialAn Aggregation Advisor for Ligand Discovery
Irwin, J. J., Duan, D., Torosyan, H., Doak, A. K., Ziebart, K. T., Sterling, T., Tumanian, G., & Shoichet, B. K. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01105 · Cited by 418
Phenotypic screens as a renewed approach for drug discovery
Zheng, W., Thorne, N., & McKew, J. C. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.07.001 · Cited by 423
Drug discovery beyond the ‘rule-of-five’
Zhang, M.-Q., & Wilkinson, B. (2007) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2007.10.005 · Cited by 418
Finding the sweet spot: the role of nature and nurture in medicinal chemistry
Hann, M. M., & Keserü, G. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3701 · Cited by 411
An Overview of Drug Discovery and Development
Berdigaliyev, N., & Aljofan, M. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0307 · Cited by 396
The styrene–maleic acid copolymer: a versatile tool in membrane research
Dörr, J. M., Scheidelaar, S., Koorengevel, M. C., Dominguez, J. J., Schäfer, M., van Walree, C. A., & Killian, J. A. (2016) · European Biophysics Journal · doi:10.1007/s00249-015-1093-y · Cited by 405
Best practices and benchmarks for intact protein analysis for top-down mass spectrometry
Donnelly, D. P., Rawlins, C. M., DeHart, C. J., Fornelli, L., Schachner, L. F., Lin, Z., Lippens, J. L., Aluri, K. C., Sarin, R., Chen, B., et al. (2019) · Nature Methods · doi:10.1038/s41592-019-0457-0 · Cited by 377
Two‐ and Three‐dimensional Rings in Drugs
Aldeghi, M., Malhotra, S., Selwood, D. L., & Chan, A. W. E. (2014) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12260 · Cited by 372
“The percentage distribution (the values next to the target classes in Figure 6) of targets among the marketed drugs set analyzed is similar to a previous study (18).”
ResultWolf, M. G., Hoefling, M., Aponte‐Santamaría, C., Grubmüller, H., & Groenhof, G. (2010) · Journal of Computational Chemistry · doi:10.1002/jcc.21507 · Cited by 372
Homology modeling in drug discovery: Overview, current applications, and future perspectives
Muhammed, M. T., & Aki‐Yalcin, E. (2019) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13388 · Cited by 358
The p KaDistribution of Drugs: Application to Drug Discovery
Manallack, D. T. (2007) · Perspectives in Medicinal Chemistry · doi:10.1177/1177391x0700100003 · Cited by 354
Molecular obesity, potency and other addictions in drug discovery
Hann, M. M. (2011) · MedChemComm · doi:10.1039/c1md00017a · Cited by 363
Sarkar, S. (2013) · Biochemical Society Transactions · doi:10.1042/bst20130134 · Cited by 370
PubChem as a public resource for drug discovery
Li, Q., Cheng, T., Wang, Y., & Bryant, S. H. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.10.003 · Cited by 365
“However, only a few drug targets are successfully used in current therapies [10].”
BackgroundAllosteric GPCR modulators: taking advantage of permissive receptor pharmacology
Leach, K., Sexton, P. M., & Christopoulos, A. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.06.004 · Cited by 363
Targeting Breast Cancer Stem Cells
Liu, S., & Wicha, M. S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.5388 · Cited by 356
Regulation of GPCR activity, trafficking and localization by GPCR‐interacting proteins
Magalhaes, A. C., Dunn, H., & Ferguson, S. S. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01552.x · Cited by 353
“The importance of GPCRs for the treatment of disease is highlighted by the fact that at least 30–40% of prescription drugs target these proteins (Overington et al., 2006).”
BackgroundChemical modulators of autophagy as biological probes and potential therapeutics
Fleming, A., Noda, T., Yoshimori, T., & Rubinsztein, D. C. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.500 · Cited by 349
“Although the modern pharmacopoeia comprises in excess of 21,000 FDA–approved drug products, when duplications (for example, different salts of the same active compound) are disregarded, it is calculated that there are only 1,204 small-molecule and 166 biological drugs currently availabl”
BackgroundHow Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets
Doak, B. C., Zheng, J., Dobritzsch, D., & Kihlberg, J. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01286 · Cited by 335
Drugging Membrane Protein Interactions
Yin, H., & Flynn, A. D. (2016) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-092115-025322 · Cited by 339
“(2) concluded that MPs constitute more than 60% of current drug targets.”
BackgroundEngineered protein scaffolds as next-generation antibody therapeutics
Gebauer, M., & Skerra, A. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.04.627 · Cited by 341
The role of kinetic context in apparent biased agonism at GPCRs
Klein Herenbrink, C., Sykes, D. A., Donthamsetti, P., Canals, M., Coudrat, T., Shonberg, J., Scammells, P. J., Capuano, B., Sexton, P. M., Charlton, S. J., et al. (2016) · Nature Communications · doi:10.1038/ncomms10842 · Cited by 328
Targeting potassium channels in cancer
Huang, X., & Jan, L. Y. (2014) · Journal of Cell Biology · doi:10.1083/jcb.201404136 · Cited by 330
“About 13% of currently known drugs whose primary therapeutic targets are ion channels are being used for the treatment of a variety of human conditions, including cardiovascular and neurological disorders (Overington et al., 2006).”
BackgroundProtein tyrosine phosphatases as potential therapeutic targets
He, R.-J., Yu, Z.-H., Zhang, R.-Y., & Zhang, Z.-Y. (2014) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.80 · Cited by 327
Heteroaromatic Rings of the Future
Pitt, W. R., Parry, D. M., Perry, B. G., & Groom, C. R. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801513z · Cited by 332
Metadata
- Authors
- Overington, J. P., Al-Lazikani, B., & Hopkins, A. L.
- Affiliations
- Pfizer (United Kingdom) (GB)
- Corresponding author
- Overington, John P.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-12
- Volume
- 5
- Issue
- 12
- Pages
- 993-996
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1968682237
- Cited by
- 3,505
- References
- 29
- Citations by year
- 2026: 82 · 2025: 126 · 2024: 117 · 2023: 127 · 2022: 173 · 2021: 168 · 2020: 190 · 2019: 190 · 2018: 198 · 2017: 215 · 2016: 276 · 2015: 268 · 2014: 245 · 2013: 280 · 2012: 247
- FWCI
- 7.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- therapeutic target, molecular targets, protein kinases, polypharmacology, approved drugs
- MeSH terms
- Humans, Technology, Pharmaceutical, Drug Design, Drugs, Investigational, Genome, Human, Drug Delivery Systems, Drug Approval
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.